Telomir Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Telomir Pharmaceuticals's earnings have been declining at an average annual rate of -1383.4%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually.
Key information
-1,383.4%
Earnings growth rate
-1,349.4%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | -624.7% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Telomir Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -19 | 3 | 2 |
31 Dec 23 | 0 | -13 | 2 | 2 |
30 Sep 23 | 0 | -4 | 2 | 2 |
30 Jun 23 | 0 | -3 | 0 | 2 |
31 Mar 23 | 0 | -1 | 0 | 1 |
31 Dec 22 | 0 | -1 | 0 | 1 |
Quality Earnings: TELO is currently unprofitable.
Growing Profit Margin: TELO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TELO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TELO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TELO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: TELO has a negative Return on Equity (-624.67%), as it is currently unprofitable.